Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Travere Therapeutics Inc
(NQ:
TVTX
)
16.57
+0.16 (+0.98%)
Streaming Delayed Price
Updated: 12:10 PM EDT, Oct 14, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Travere Therapeutics Inc
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Travere Therapeutics Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI® Demonstrating Long-Term Kidney Function Preservation in IgA Nephropathy; Narrowly Missing eGFR Total Slope Endpoint versus Active Control, Irbesartan
September 21, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Broadcom, KB Home And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
September 21, 2023
U.S. stock futures traded lower this morning on Thursday. Here are some big stocks recording losses in today’s pre-market trading session.
Via
Benzinga
Evercore ISI Group Maintains Outperform Rating for Travere Therapeutics: Here's What You Need To Know
September 19, 2023
Via
Benzinga
Analyst Ratings for Travere Therapeutics
September 06, 2023
Via
Benzinga
The Latest Analyst Ratings for Travere Therapeutics
August 18, 2023
Via
Benzinga
Earnings Scheduled For August 3, 2023
August 03, 2023
Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is likely to report quarterly earnings at $1.10 per share on revenue of $512.74 million.
Via
Benzinga
Expert Ratings for Travere Therapeutics
July 18, 2023
Via
Benzinga
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 11, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
EXCLUSIVE: Kidney Care Revolution? How Swedish Biopharma Calliditas Aims To Tackle A Rare Disease With 'Unique, But Pretty Simple' Drug
September 08, 2023
Calliditas, a rare disease company focused on kidney ailments, is optimistic of its lead drug taking off in a big way.
Via
Benzinga
Mirum Pharmaceuticals Completes Acquisition of Bile Acid Product Portfolio for Treatment of Rare Liver Diseases from Travere Therapeutics
September 05, 2023
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Analyst Ratings for Travere Therapeutics
June 07, 2023
Via
Benzinga
Travere Therapeutics Completes Sale of Bile Acid Product Portfolio to Mirum Pharmaceuticals
September 05, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics to Present at the 2023 Wells Fargo Healthcare Conference
August 31, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2023
August 24, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 14, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
NASDAQ: TVTX Investor Notice: Investigation Concerning Potential Securities Laws Violations by Travere Therapeutics, Inc.
August 10, 2023
San Diego, CA -- (SBWIRE) -- 08/10/2023 -- Travere Therapeutics, Inc. is under investigation over potential securities laws violations in connection with certain financial statements.
Via
SBWire
Travere Therapeutics Reports Second Quarter 2023 Financial Results
August 03, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
3 Small-Cap Stocks That Could Be Big-Time Winners
July 22, 2023
These stocks come with significant risks. But they could generate huge returns over time.
Via
The Motley Fool
Biotech Stock Travere Therapeutics Is Trading At A Deep Discount: JPMorgan
July 21, 2023
Travere Therapeutics shares have lost nearly 30% since early May.
Via
Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For July 21, 2023
July 21, 2023
Via
Benzinga
Travere Therapeutics to Report Second Quarter 2023 Financial Results
July 20, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics Offloads Bile Acid Product Portfolio: Says Divestment Strengthens Financial Foundation
July 17, 2023
Travere Therapeutics Inc (NASDAQ: TVTX) has agreed to sell its bile acid product portfolio that, which includes Cholbam (cholic acid) and Chenodal (chenodiol), two medications, to Mirum Pharmaceuticals...
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
July 17, 2023
Via
Benzinga
Mirum Pharmaceuticals Enters Agreement to Acquire Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases from Travere Therapeutics
July 17, 2023
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Travere Therapeutics Enters Agreement to Sell its Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases to Mirum Pharmaceuticals
July 17, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 11, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Meet Chinook Therapeutics, The Company Novartis Is Spending $3.5 Billion To Acquire
July 05, 2023
Chinook Therapeutics has a history of being opportunistic. Now, it's joining forces with Novartis.
Via
Investor's Business Daily
Travere Therapeutics Announces Presentations of Abstracts at the 60th European Renal Association (ERA) Congress 2023
June 08, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
3 Biotech Stocks That Could Skyrocket in the Next 12 Months
June 07, 2023
These promising biotech stocks are risky but offer tremendous upside generating stellar long-term returns in the upcoming 12 months.
Via
InvestorPlace
Travere Therapeutics to Present at Upcoming Investor Conferences
June 01, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.